Overview

Lesinurad/Allopurinol 200/300 FDC Tablets Bioavailability

Status:
Completed

Trial end date:
2016-08-01

Target enrollment:

Participant gender:

Summary

This study will assess relative bioavailability of lesinurad/allopurinol fixed dose combination (FDC), its individual components and the effect of food.

Phase:

Phase 1

Details

Lead Sponsor:

Ardea Biosciences, Inc.

Treatments:

Allopurinol
Lesinurad